Who are ABP 692's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lecanemab IV, Lecanemab SC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abp-692.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ABP 692 — Competitive Intelligence Brief

ABP 692 (ABP 692) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (anti-amyloid-beta). Area: Neurology.

phase 3 Monoclonal antibody (anti-amyloid-beta) Amyloid-beta protofibrils Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ABP 692 (ABP 692) — Amgen. ABP 692 is a monoclonal antibody that targets amyloid-beta protofibrils to reduce amyloid pathology in Alzheimer's disease.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABP 692 TARGET	ABP 692	Amgen	phase 3	Monoclonal antibody (anti-amyloid-beta)	Amyloid-beta protofibrils
Lecanemab IV	Lecanemab IV	Eisai Inc.	phase 3	Monoclonal antibody (anti-amyloid-beta)	Amyloid-beta protofibrils
Lecanemab SC	Lecanemab SC	Eisai Inc.	phase 3	Monoclonal antibody (anti-amyloid-beta)	Amyloid-beta protofibrils

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (anti-amyloid-beta) class)

Eisai Inc. · 2 drugs in this class
Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABP 692 — Competitive Intelligence Brief. https://druglandscape.com/ci/abp-692. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab